EVO ICL™

A Modern, Reversible Alternative to LASIK

EVO ICL Overview

EVO ICL stands for EVO Implantable Collamer Lens; it is the current generation of the Visian ICL, the implantable collamer lens Dr. Feinerman has implanted since its 2005 FDA approval. It is an advanced phakic intraocular lens, FDA-approved for adults ages 21 to 60, designed to correct moderate to high myopia and myopic astigmatism. Unlike LASIK, EVO ICL does not alter the cornea at all. A micro-thin, biocompatible lens is placed inside the eye, just behind the iris and in front of the natural lens. Nothing is removed. The cornea is preserved, the natural lens is preserved, and the eye’s ability to focus through its own accommodation is preserved.

The lens is made of Collamer, a proprietary material composed of collagen and a biocompatible polymer. Collamer works in harmony with the eye’s own chemistry, carries built-in UV protection, and is designed for long-term implantation.

Dr. Feinerman was the first surgeon in California to implant the Visian ICL after FDA approval in 2005. He was also among the first in California to implant the EVO ICL after it was FDA approved in 2022. Together, that represents more than 20 years of clinical experience with the implantable collamer lens.

EVO ICL at a Glance

FDA-approved for adults ages 21 to 60
Treats nearsightedness from -3.00 to -20.00 diopters, with or without astigmatism
Preserves the cornea: no tissue is removed
Preserves the natural lens: accommodation is unaffected
Built-in UV protection in the Collamer lens material
10 to 15 minutes per eye with rapid visual recovery
Reversible: the lens can be removed if ever needed
More than 4 million implantable collamer lenses sold worldwide
99.4% patient satisfaction rate among patients studied

Our EVO ICL Process

Consultation

Every patient begins with a comprehensive eye exam and consultation with Dr. Feinerman. This includes detailed corneal imaging, anterior segment evaluation, axial length measurement, endothelial cell count, UBM AI^TM imaging of the structures behind the iris for precise EVO ICL sizing, and a careful review of your prescription history and visual goals. Dr. Feinerman will explain the procedure in detail, answer every question, and determine whether EVO ICL is the right option for your eyes.

Procedure

Our staff ensures you are reclined and comfortable. The EVO ICL procedure, performed by Dr. Feinerman, is generally painless and takes only about 10-15 minutes per eye. Patients generally recover very quickly following treatment (within a few hours).

Post-op

After the procedure, Dr. Feinerman personally calls his patients to ensure they are doing well and to address any questions. During your actual in-person post-op visit, Dr. Feinerman will perform a final examination to ensure recovery is complete.

At a Glance: Side-by-Side Comparison

Feature	LASIK	EVO ICL
FDA-Approved Age Range	Generally ages 18 and older	Ages 21 to 60
How It Works	Removes corneal tissue to reshape the eye	Adds a biocompatible lens behind the iris ✓
Prescription Range	Limited at higher myopia	Broad, including moderate-to-high myopia ✓
Long Eyes (axial length > 26 mm)	Limited by corneal thickness	Often the safest first option ✓
Corneal Thickness	Minimum thickness required	No corneal thickness requirement ✓
Dry Eye Impact	Flap disrupts corneal nerves	Minimal impact on corneal nerves ✓
Native Accommodation	Preserved (lens is untouched)	Preserved (lens is untouched)
Reversibility	Permanent. Tissue cannot be replaced	Reversible (lens can be removed) ✓
Future IOL Options	Trifocal IOLs typically not the right match	Full menu of premium IOLs preserved ✓
UV Protection	None	Built into the Collamer lens material ✓
Procedure Time	About 15 minutes for both eyes	10 to 15 minutes per eye
Visual Recovery	Fast, hours to one day	Fast, hours to one day

Understanding the Two Procedures

What Is LASIK?

LASIK (Laser-Assisted In Situ Keratomileusis) corrects vision by reshaping the cornea, the clear front surface of the eye. A thin corneal flap is created with a femtosecond laser, an excimer laser removes a precise amount of tissue to flatten or steepen the corneal curvature, and the flap is repositioned. For the right candidate, LASIK is fast, safe, and produces excellent outcomes. The most advanced LASIK platform available in the United States, WaveLight^® Plus LASIK with INNOVEYES SightMap™, is performed at Feinerman Vision.

LASIK has clear limitations, however. The procedure is fundamentally subtractive: it works by permanently removing corneal tissue. The higher the prescription, the more tissue must be removed, and at some point that is no longer safe or optically reliable. Corneal thickness becomes a gating factor, and the flap creation process temporarily disrupts the corneal nerves that regulate tear production.

What Is EVO ICL?

As covered in the overview above, EVO ICL is a phakic intraocular lens placed inside the eye. Unlike LASIK, it does not alter the cornea at all. A micro-thin, biocompatible lens is placed inside the eye, positioned just behind the iris and in front of the natural lens. Nothing is removed. The cornea is preserved, the natural lens is preserved, and the eye’s ability to focus through its own accommodation is preserved.

Each eye takes 10 to 15 minutes in the surgery center. Most patients experience dramatically improved vision within hours and return to normal activities the following day.

An important distinction: EVO ICL is additive, not subtractive. It corrects vision without removing any tissue from the cornea and without removing the natural lens. The eye’s natural structure is preserved, and the procedure can be reversed if ever needed.

A Globally Validated Technology

More than 4 million implantable collamer lenses have been sold worldwide, and among patients studied, the implantable collamer lens carries a 99.4% satisfaction rate. This is one of the most validated lens technologies in modern ophthalmology, with decades of clinical data supporting its safety and long-term performance.

EVO ICL has become a procedure of choice for athletes, performers, and public figures whose careers depend on exceptional vision. Patients who have shared their EVO ICL experience publicly include Joe Jonas of the Jonas Brothers, Max Strus of the NBA’s Cleveland Cavaliers, and content creator Julienne By. Their experiences underscore why EVO ICL is increasingly the preferred choice for patients who demand both visual performance and long-term flexibility.

Why EVO ICL Outperforms LASIK for Certain Eyes

High Prescriptions and Long Eyes

LASIK works by removing corneal tissue to reshape the eye’s focusing surface. The higher the prescription, the more tissue must be removed. Beyond a certain point, removing enough tissue to fully correct the prescription either produces unreliable results (regression of the correction, poor night vision, or glare and halos) or compromises the structural integrity of the cornea. Patients with high myopia are turned away from LASIK entirely.

EVO ICL does not depend on corneal tissue. Because it adds a corrective lens rather than subtracting tissue, it delivers sharp, stable vision across a much broader range of prescriptions, including prescriptions that LASIK simply cannot safely address. For patients with a spherical equivalent ranging from -3.00 to -20.00 diopters, particularly those with long eyes (an axial length above 26 millimeters), EVO ICL is often the safest first option. Long, highly myopic eyes carry an elevated lifetime risk of retinal detachment, and removing the natural lens (as in refractive lens exchange) can amplify that risk. EVO ICL preserves both the cornea and the natural lens, which is why it remains our preferred option for these patients in their 20s, 30s, 40s, and 50s.

How I Decide: The PTA Framework

The decision to recommend EVO ICL over LASIK at high prescriptions is grounded in a clinical framework called Percent Tissue Altered (PTA), validated by Santhiago, Randleman, and colleagues in a landmark 2014 study in the American Journal of Ophthalmology. Read the full breakdown of the PTA math, the night vision physics, and why EVO ICL outperforms LASIK at the high end of the prescription range.

Read: EVO ICL for High Prescriptions →

Thin Corneas

Some patients have corneas that are healthy but naturally thinner than average. LASIK requires a minimum corneal thickness to maintain the eye’s long-term structural integrity. Removing tissue from an already-thin cornea raises the risk of post-surgical instability and compromised outcomes.

Because EVO ICL preserves 100% of the cornea, corneal thickness is not a limiting factor. Patients who have been told they cannot have LASIK because of thin corneas are frequently excellent candidates for EVO ICL.

Dry Eye Concerns

LASIK involves creating a corneal flap, which temporarily severs a portion of the corneal nerves responsible for tear production and ocular surface sensation. The vast majority of patients recover well, but patients who already have dry eye tendencies, or whose lifestyle, hormonal status, or environment predisposes them to dry eye, can experience meaningful symptoms after LASIK.

EVO ICL is performed through a tiny incision at the edge of the cornea and does not disturb the corneal nerves in the same way. For patients with dry eye risk factors, EVO ICL is a markedly gentler option, and post-operative dry eye is significantly less common. Read our full discussion of EVO ICL and dry eye, including a patient who had EVO ICL in one eye and LASIK in the other.

When LASIK May Still Be the Right Choice

LASIK remains an outstanding procedure for the right candidate, and we perform it often at Feinerman Vision. For patients in their 20s and 30s with a stable prescription, a healthy cornea of adequate thickness, and a still-clear natural lens, corneal laser surgery is faster, less invasive, and the first conversation we have. WaveLight^® Plus LASIK with INNOVEYES SightMap brings a level of optical customization that earlier laser platforms could not match, and for the right cornea it is an exceptional choice.

The right procedure depends on the eye in front of us. EVO ICL is not a universally better option. It is the better option for specific patients: those with prescriptions or anatomy that put them outside the LASIK range, those with dry eye risk, and those who want to preserve the broadest possible set of lens options for the decades ahead, when dysfunctional lens syndrome and cataracts inevitably develop.

Weighing your options? Read our EVO ICL vs. LASIK comparison for a side-by-side look at candidacy, corneal impact, dry eye, and long-term flexibility.

The Reversibility Advantage: A Benefit Measured in Decades

One of the most important, and most under-discussed, advantages of EVO ICL is that it is reversible. The lens can be removed or exchanged by a qualified surgeon in a straightforward procedure if your needs ever change.

LASIK is not reversible. Once corneal tissue has been removed, it cannot be replaced, and the cornea’s curvature and biomechanics are permanently altered. This distinction matters enormously when we think about what happens to the human eye with time.

Preserving Native Accommodation

The natural lens of a younger patient does something no artificial lens can fully replicate: it changes shape to focus at near, intermediate, and distance ranges. This is called accommodation, and it is what allows a healthy 30-year-old to read a book and then look up at a distant sign without effort.

EVO ICL preserves this. Because the natural lens is left untouched, the eye’s own accommodation continues to work the way it always has. Lens replacement procedures, including refractive lens exchange and cataract surgery, by definition remove this natural accommodation. For patients still in their 20s, 30s, and 40s, that is one more reason EVO ICL is often the right answer for now, even when a lens-based procedure may eventually be the right answer later.

Presbyopia and Dysfunctional Lens Syndrome

Every patient, regardless of refractive history, will eventually develop presbyopia, the age-related loss of near focus that typically begins in the mid-40s. Over the following years and decades, the natural lens continues to stiffen, yellow, and lose clarity, a progression now recognized as dysfunctional lens syndrome (DLS). DLS ultimately evolves into cataract, at which point the natural lens must be replaced with an intraocular lens (IOL).

This is where the choice made decades earlier, LASIK or EVO ICL, becomes unexpectedly consequential.

Why Prior LASIK Limits Future Lens Options

Modern cataract and refractive lens surgery offers an exceptional menu of IOL technologies: monofocal lenses, the Light Adjustable Lens™ (LAL®), extended depth-of-focus lenses such as Clareon^® Vivity^® and trifocal lenses including Clareon^® PanOptix^® Pro, FINEVISION HP, and enVista Envy™. Premium IOLs can deliver a range of vision (distance, intermediate, and near) that meaningfully reduces or eliminates dependence on glasses.

Prior LASIK changes this calculus. Because LASIK permanently alters the cornea’s shape, calculating the correct IOL power is less predictable, and the optical irregularities introduced by LASIK often reduce the visual quality from advanced multifocal and trifocal IOLs. The Light Adjustable Lens has emerged as a particularly strong option for post-LASIK patients precisely because its prescription can be adjusted after surgery to compensate for that reduced predictability. But the broader menu of trifocal IOLs, which deliver the highest rates of complete glasses independence, are typically not the right match for post-LASIK eyes.

Why Prior EVO ICL Preserves Every Future Option

Patients who chose EVO ICL earlier in life are in a fundamentally different position. When presbyopia, dysfunctional lens syndrome, or cataract eventually requires lens-based surgery, the EVO ICL is simply removed. The cornea is untouched, IOL calculations are as accurate as they would be in any unoperated eye, and the patient retains access to the full menu of IOL technologies, including the trifocal lenses that LASIK patients typically cannot use.

Just as importantly, these patients remain candidates for future technologies that have not yet been invented. Lens design and refractive surgery continue to advance rapidly, and an untouched cornea is the best possible platform for whatever emerges over the next two or three decades.

Choosing EVO ICL today is, in a very real sense, a decision that protects your options tomorrow. For patients in their 20s, 30s, and 40s, preserving the ability to choose any future IOL technology, including technologies that do not yet exist, is one of the most compelling reasons to select EVO ICL over LASIK.

For the full argument, read our companion page: EVO ICL and the choices you keep.

To see this in motion, explore our interactive 3D tour of the EVO ICL™: where the lens sits behind the iris, and how it can be removed.

See This in Practice

Last month, a patient I implanted with an ICL in 2006 flew back to Newport Beach from Honolulu so I could remove it and perform refractive lens exchange. After 20 years inside her eye, the original ICL came out perfectly clear in under a minute, and she now sees 20/20 at distance, intermediate, and near, glasses-free for the first time in 50 years.

Read the full case study →

Precision Sizing with UBM AI^TM + ICLguru^®

In EVO ICL surgery, sizing is everything. The lens must vault precisely above the natural lens, and achieving the ideal vault depends on measuring structures that sit behind the iris, hidden from conventional imaging.

Dr. Feinerman uses UBM AI^TM (high-resolution ultrasound biomicroscopy enhanced with artificial intelligence) to image those structures directly, including the ciliary sulcus where the lens will rest. The high-resolution images are then processed through ICLguru^®, an AI-powered planning platform developed under the leadership of Dr. Roger Zaldivar that integrates UBM measurements with other anterior segment biometrics to recommend an optimal lens size and predict the postoperative vault before surgery is ever performed. This goes beyond the traditional white-to-white sizing method, which estimates internal anatomy from the visible diameter of the cornea.

Multicenter clinical research has demonstrated that this combined methodology predicts postoperative vault with clinically meaningful accuracy, and is now used by leading EVO ICL surgeons around the world. For Dr. Feinerman’s patients, that translates to a measurably lower likelihood of needing a lens exchange and a more predictable visual outcome.

Most refractive practices still rely on the FDA-approved white-to-white sizing method alone. Adding UBM AI plus ICLguru® is a deliberate investment in precision that not every practice makes, and it reflects the boutique, single-surgeon standard of care at Feinerman Vision.

Where EVO ICL Fits in Your Vision Journey

Vision correction is not a single decision. The right procedure at age 30 may be different from the right procedure at age 55, because the underlying anatomy of the eye changes with time. The cornea, the natural lens, and the way the eye focuses all evolve. The most thoughtful refractive plan recognizes this and chooses the procedure that fits both today and tomorrow.

This is where EVO ICL has a uniquely valuable position. It corrects vision now, in the prescription range that LASIK often cannot reach safely, while preserving every option for the future.

Procedure	Typical Age	What It Does	Long-Term Note
LASIK	20s to early 40s	Reshapes the cornea with excimer laser. Permanent change.	Does not stop lens aging or future cataract.
EVO ICL	21 to 60	Adds a Collamer lens behind the iris. Reversible.	Preserves the cornea, the natural lens, and accommodation.
Refractive Lens Exchange (RLE)	50 and above	Removes the aging natural lens; replaces it with a customized IOL.	Eliminates need for future cataract surgery.
Cataract Surgery	Typically 60+	Same surgical platform as RLE. Insurance-covered when a cataract is medically significant.	Premium IOL upgrades available at the time of surgery.

For patients ages 21 to 60 with moderate to high myopia, EVO ICL is often the strongest first option. For patients in their late 40s, 50s, and 60s where the natural lens is becoming the source of the problem, refractive lens exchange may be the better long-term answer. Dr. Feinerman will walk you through the tradeoffs based on the specific anatomy of your eyes.

The market is moving the same direction. US laser vision correction volume fell 52 percent from 2022 to 2026 while EVO ICL adoption rose 76 percent; our post on why vision correction is shifting from laser to lens explains what is driving it and where LASIK still belongs.

Who May Be a Candidate for Each?

LASIK May Be Appropriate For	EVO ICL May Be Ideal For
Adults 18 and older with a stable prescription for at least one year Low to moderate myopia, low to moderate hyperopia, and astigmatism within safe ablation limits Adequate corneal thickness on imaging Healthy tear film and no significant dry eye Patients comfortable with a permanent corneal procedure	Adults ages 21 to 60 Moderate to high myopia (spherical equivalent of -3.00 to -20.00 diopters), with or without astigmatism Long eyes with axial length above 26 millimeters Thin corneas or corneas unsuitable for tissue removal Existing dry eye or risk factors for dry eye Patients who want to preserve the full menu of future lens options Patients who prefer a reversible procedure Professionals and lifestyles that demand high-definition vision

LASIK May Be Appropriate For

EVO ICL May Be Ideal For

Adults 18 and older with a stable prescription for at least one year
Low to moderate myopia, low to moderate hyperopia, and astigmatism within safe ablation limits
Adequate corneal thickness on imaging
Healthy tear film and no significant dry eye
Patients comfortable with a permanent corneal procedure

Adults ages 21 to 60
Moderate to high myopia (spherical equivalent of -3.00 to -20.00 diopters), with or without astigmatism
Long eyes with axial length above 26 millimeters
Thin corneas or corneas unsuitable for tissue removal
Existing dry eye or risk factors for dry eye
Patients who want to preserve the full menu of future lens options
Patients who prefer a reversible procedure
Professionals and lifestyles that demand high-definition vision

The right procedure depends on your prescription, corneal anatomy, retinal health, age, lifestyle, and visual goals. A comprehensive evaluation is the only way to determine which option is appropriate for your eyes. For the complete picture of who qualifies and who does not, read my EVO ICL candidate guide.

A look into the procedure

Cleveland Cavaliers star Max Strus upgraded his vision with
EVO ICL

Julienne By's Evo ICL
experience

The Surgeon Factor

Technology alone does not determine outcomes. The surgeon’s experience, approach to planning, and continuity of care matter equally. At most high-volume vision correction centers, patients rotate between staff for consultations, testing, and follow-up. The surgeon may be performing dozens of procedures a day with limited time for individual assessment. This is not the model that produces the best outcomes for every patient.

Dr. Gregg Feinerman’s Background

Dr. Feinerman is board-certified by the American Board of Ophthalmology and holds a Fellow designation from the American College of Surgeons (FACS). He completed his refractive surgery fellowship at the internationally acclaimed Gimbel Eye Center in Calgary under Howard V. Gimbel, MD, where he trained on the Implantable Collamer Lens years before its FDA approval in the United States. Through 2019, he served as adjunct clinical professor of ophthalmology at the University of Southern California. He has been practicing intraocular and refractive surgery in Newport Beach since 2001.

Across more than two decades, Dr. Feinerman has been an early adopter of the technologies that have shaped modern refractive and lens-based surgery. He was the first surgeon in Southern California to implant a premium IOL after FDA approval, and the first to implant a premium IOL in a Medicare patient. He was also the first on the West Coast to perform Ziemer bladeless LASIK, and the first in Orange County and greater Los Angeles to perform WaveLight^® Plus LASIK following its FDA approval. He has served as Principal Investigator on more than ten FDA-registered clinical trials for intraocular lens and ophthalmic surgical technology.

Dr. Feinerman was the first surgeon in California to implant the Visian ICL after FDA approval in 2005, and among the first in California to implant the EVO ICL after its 2022 approval, representing more than 20 years of clinical experience with the implantable collamer lens. Few surgeons in Southern California can offer that depth of EVO ICL experience.

How Dr. Feinerman Approaches Every Case

✓ All consultations are conducted personally by Dr. Gregg Feinerman
✓ Surgical planning is reviewed directly by your surgeon, not delegated
✓ There is no co-management model with outside optometrists
✓ Dr. Feinerman performs every procedure himself
✓ Postoperative care includes direct surgeon follow-up at every visit
✓ Special attention to patients with professional visual requirements, including pilots, athletes, and military personnel

Refractive surgery is elective. Precision, continuity, and trust in your surgeon matter as much as the technology on the platform.

LASIK remains an outstanding procedure for the right candidate. But LASIK is subtractive and permanent. For patients whose prescriptions, corneal anatomy, dry eye profile, or long-term planning priorities make LASIK a less-than-ideal match, EVO ICL is the technically superior choice.

EVO ICL corrects vision without altering the cornea, accommodates a broader range of myopia and astigmatism, preserves the eye’s natural accommodation, is gentler on the ocular surface, and is reversible. That reversibility preserves every future lens option, including the trifocal IOLs that are typically not recommended for post-LASIK eyes, and every technology yet to be developed.

The most important step is a detailed evaluation to determine which technology is right for your eyes, your lifestyle, and your visual goals.

Weighing LASIK or ICL? Our complete LASIK vs ICL guide compares the two side by side, from candidacy and cost to dry eye and reversibility.

Dr. Feinerman personally conducts every evaluation · Newport Beach, CA · (949) 631-4780

EVO ICL™ for Orange County and Greater Los Angeles

Feinerman Vision is a boutique, single-surgeon practice in Newport Beach, and Dr. Feinerman personally performs every consultation and every EVO ICL procedure. Patients travel to our Newport Beach office from across Orange County and the greater Los Angeles area, including Irvine, Costa Mesa, Huntington Beach, Long Beach, and the surrounding coastal and inland communities, because the care comes from the surgeon himself rather than a rotating team. Los Angeles patients: see our EVO ICL for Los Angeles patients page for travel logistics, visit planning, and pricing. If you have been searching for an EVO ICL surgeon near you and want an honest evaluation of whether the lens is right for your eyes, our Newport Beach practice is a short drive from most of Orange County and much of the South Bay and Long Beach area. Dr. Feinerman calls each patient the evening of surgery and sees them himself the following day, with no hand-offs to outside providers. Schedule your consultation with Dr. Feinerman to review your candidacy, your prescription, and your long-term options in person.

FAQs

What is the EVO ICL Lens?

EVO ICL stands for EVO Implantable Collamer Lens; it is the current generation of the Visian ICL, the implantable collamer lens Dr. Feinerman has implanted since its 2005 FDA approval. It is an advanced phakic intraocular lens that corrects nearsightedness and astigmatism by adding a micro-thin biocompatible lens behind the iris and in front of the natural lens. Unlike LASIK, no corneal tissue is removed and the natural lens is preserved.

Who is a candidate for EVO ICL?

Ideal candidates are adults ages 21 to 60 with moderate to high nearsightedness (a spherical equivalent of -3.00 to -20.00 diopters), with or without astigmatism, who have had a stable prescription for at least one year and have good ocular health (no glaucoma, iritis, or significant diabetic eye disease). EVO ICL is particularly well suited for patients with thin corneas, dry eye, or long eyes that fall outside the safe LASIK range.

How long does the procedure take?

The EVO ICL procedure typically takes 10 to 15 minutes per eye. Most patients return home the same day and resume normal activities the following day.

Will I be able to feel the EVO ICL Lens?

No. The lens does not adhere to any structures within the eye. Patients do not feel the lens.

Will other people be able to see the EVO ICL Lens?

No. The EVO ICL is positioned behind the iris (the colored part of the eye), where it is invisible to the naked eye. Only an eye doctor can detect it during examination.

Can the EVO ICL Lens be removed?

Yes. The EVO ICL is designed for long-term implantation, but it can be removed or exchanged by your surgeon at any point in the future. This reversibility is one of the most important advantages of EVO ICL over LASIK.

Does EVO ICL eliminate the need for reading glasses?

EVO ICL corrects distance vision. Like LASIK, it does not eliminate presbyopia (the age-related loss of near focus that begins in the mid-40s). Patients may still require reading glasses at some point, even if they have never worn them before. When presbyopia or dysfunctional lens syndrome eventually requires lens-based surgery, the EVO ICL is removed and replaced with an intraocular lens that can address near vision.

What are the risks of EVO ICL?

As with any surgical procedure, there are risks. Potential complications, although rare, include inflammation, increased eye pressure, loss of corneal endothelial cells, the need for an additional procedure (such as a lens exchange or repositioning), and cataract formation. In Dr. Feinerman’s practice, these are mitigated through thorough preoperative evaluation, UBM AI^TM + ICLguru^® measurements, careful surgical technique, and direct postoperative monitoring.

How much does EVO ICL cost?

At Feinerman Vision, EVO ICL surgery is $9,450 for both eyes, all-inclusive: the custom lenses, surgeon fee, surgery center, anesthesia, and all routine postoperative visits with Dr. Feinerman. Astigmatism correction is included, with no add-on fees. Financing plans are available, and FSA and HSA funds may be used; see our full EVO ICL cost guide and financing options. Pricing is subject to change; the figure quoted at your consultation is the one that applies.

How does EVO ICL compare to LASIK?

LASIK reshapes the cornea by removing tissue. EVO ICL adds a corrective lens inside the eye without removing any tissue. For patients with healthy, adequately thick corneas and a prescription within the LASIK range, LASIK is a great choice. For patients with higher prescriptions, thinner corneas, dry eye risk factors, or long-term planning priorities, EVO ICL is frequently the better option. Dr. Feinerman will evaluate both pathways at your consultation.

Important Safety Information

The EVO ICL lens is intended to correct or reduce nearsightedness between -3.0 D and -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO ICL corrects for distance vision, it does not eliminate the need for reading glasses; you may require them at some point, even if you have never worn them before.

Since implantation of the EVO ICL is a surgical procedure, before considering EVO ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts.

You should NOT have EVO ICL surgery if your doctor determines that (1) the shape of your eye is not appropriate, (2) you do not meet the minimum endothelial cell density for your age at the time of implantation, (3) you have moderate to severe glaucoma, (4) your vision is not stable, or (5) you are pregnant or nursing.

For additional information about potential benefits, risks, and complications, please visit DiscoverICL.com.

Candidacy Quiz

Anyone over the age of eighteen who has not had a significant change in vision over the past 6 months and can see clearly with contact lenses or glasses may be a good candidate for LASIK or one of our other vision correction procedures. Take our LASIK candidacy test to find out more.

Savings
Calculator